BETAHISTINE GxP betahistine dihydrochloride 16 mg tablets blister packs

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

betahistine dihydrochloride, Quantity: 16 mg

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

betahistine dihydrochloride

formulario farmacéutico:

Tablet, uncoated

Composición:

Excipient Ingredients: purified talc; mannitol; microcrystalline cellulose; citric acid; colloidal anhydrous silica

Vía de administración:

Oral

Unidades en paquete:

10 tablets, 30 tablets, 60 tablets, 100 tablets, 25 tablets

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Meniere's Syndrome as defined by the following core symptoms: vertigo (with nausea/vomiting), hearing loss (hardness of hearing) and tinnitus.

Resumen del producto:

Visual Identification: Uncoated, round, biconvex, white to light creamy tablets, with a groove on one surface.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estado de Autorización:

Licence status A

Fecha de autorización:

2014-08-14